Norden Group LLC Purchases Shares of 8,858 DexCom, Inc. (NASDAQ:DXCM)

Norden Group LLC purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 8,858 shares of the medical device company’s stock, valued at approximately $689,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Versant Capital Management Inc acquired a new stake in shares of DexCom during the 4th quarter valued at $25,000. Private Trust Co. NA lifted its position in shares of DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after acquiring an additional 245 shares during the last quarter. Heck Capital Advisors LLC acquired a new stake in shares of DexCom during the 4th quarter valued at $38,000. Midwest Capital Advisors LLC acquired a new stake in shares of DexCom during the 4th quarter valued at $54,000. Finally, Rothschild Investment LLC lifted its position in shares of DexCom by 250.5% during the 4th quarter. Rothschild Investment LLC now owns 750 shares of the medical device company’s stock valued at $58,000 after acquiring an additional 536 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

DXCM has been the subject of a number of recent research reports. Canaccord Genuity Group increased their price objective on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and increased their target price for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Citigroup increased their target price on DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Finally, Wells Fargo & Company increased their target price on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $99.06.

Insiders Place Their Bets

In other news, COO Jacob Steven Leach sold 2,634 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the sale, the chief operating officer now directly owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the sale, the chief executive officer now directly owns 319,037 shares in the company, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 38,083 shares of company stock valued at $3,309,794 over the last three months. 0.30% of the stock is currently owned by insiders.

DexCom Trading Down 2.7 %

DexCom stock opened at $85.99 on Tuesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The company has a market capitalization of $33.60 billion, a price-to-earnings ratio of 60.13, a PEG ratio of 2.30 and a beta of 1.14. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company’s fifty day moving average price is $84.82 and its two-hundred day moving average price is $76.85.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.